Non-Viral nanosystems for gene and small interfering RNA delivery to the central nervous system: Formulating the solution

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3469-3484

  O'Mahony, Aoife M ^a   Godinho, Bruno M D C ^a   Cryan, John F ^a   O'Driscoll, Caitriona M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Blood brain barrier; CNS; Extracellular barriers; Formulation; Intracellular barriers; Non viral gene delivery; RNAi; Targeted drug delivery

Indexed keywords

ADAMANTANE; AMYLOID PRECURSOR PROTEIN; BETA CATENIN; BETA SECRETASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CATIONIC LIPOSOME; CATIONIC POLYMER; CELL PENETRATING PEPTIDE; CYCLODEXTRIN; DENDRIMER; DOXORUBICIN; ENVELOPE PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; HUNTINGTIN; IMMUNOLIPOSOME; LIPOSOME; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NANOCARRIER; NUCLEIC ACID; PEPTIDOMIMETIC AGENT; POLYAMIDOAMINE; POLYMER; PRION PROTEIN; PROTEIN C JUN; SMALL INTERFERING RNA; STEALTH LIPOSOME; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CIRCULATION; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG UPTAKE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; IRON TRANSPORT; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PERMEABILITY BARRIER; RETICULOENDOTHELIAL SYSTEM; SPINAL CORD; TOXICITY;

BLOOD BRAIN BARRIER; CNS; EXTRACELLULAR BARRIERS; FORMULATION; INTRACELLULAR BARRIERS; NON-VIRAL GENE DELIVERY; RNAI; TARGETED DRUG DELIVERY;

ANIMALS; CENTRAL NERVOUS SYSTEM; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; PHARMACEUTICAL SOLUTIONS; RNA, SMALL INTERFERING;

EID: 84883895720     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23672     Document Type: Review

References (181)

1. Guo J, Fisher KA, Darcy R, Cryan JF, O'Driscoll C 2010. Therapeutic targeting in the silent era: Advances in non-viral siRNA delivery. Mol BioSyst 6(7):1143-1161.
2. Davidson BL, McCray PB Jr. 2011. Current prospects for RNA interference-based therapies. Nat Rev Genet 12(5):329-340.
3. Kole R, Krainer AR, Altman S. 2012. RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125-140.
4. Boudreau RL, Davidson BL. 2010. RNAi therapeutics for CNS disorders. Brain Res 1338:112-121.
5. Boudreau RL, Rodríguez-Lebrón E, Davidson BL. 2011. RNAi medicine for the brain: Progresses and challenges. Hum Mol Genet 20(R1):R21-R27.
6. Bumcrot D, Manoharan M, Koteliansky V, Sah DWY. 2006. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat Chem Biol 2(12):711-719.
7. Fountaine TM, Wood MJA, Wade-Martins R 2005. Delivering RNA interference to the mammalian brain. Curr Gene Ther 5(4):399-410.
8. Davidson BL, Breakefield XO. 2003. Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 4(5):353-364.
9. Harper SQ, Staber PD, He XH, Eliason SL, Martins IH, Mao QW, Yang L, Kotin RM, Paulson HL, Davidson BL. 2005. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102(16):5820-5825.
10. Xia HB, Mao QW, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL. 2004. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10(8):816-820.
11. Grondin R, Kaytor MD, Ai Y, Nelson PT, Thakker DR, Heisel J, Weatherspoon MR, Blum JL, Burright EN, Zhang Z, Kaemmerer WF. 2012. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135(4):1197-1209.
12. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E. 2005. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8(10):1343-1349.
13. Bergen JM, Park IK, Horner PJ, Pun SH. 2008. Nonviral approaches for neuronal delivery of nucleic acids. Pharm Res 25(5):983-998.
14. Thomas CE, Ehrhardt A, Kay MA. 2003. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4(5):346-358.
15. Scholz C, Wagner E. 2012. Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriers. J Control Release 161(2):554-565.
16. Lei ZN, Zhang LM, Sun FY. 2008. [Beta]-catenin siRNA inhibits ischemia-induced striatal neurogenesis in adult rat brain following a transient middle cerebral artery occlusion. Neurosci Lett 435(2):108-112.
17. Salahpour A, Medvedev IO, Beaulieu JM, Gainetdinov RR, Caron MG. 2007. Local knockdown of genes in the brain using small interfering RNA: A phenotypic comparison with knockout animals. Biol Psychiatry 61(1):65-69.
18. Tan PH, Yang LC, Shih HC, Lan KC, Cheng JT. 2005. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther 12(1):59-66.
19. Boussif O, Lezoualch F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture and in-vivo-Polyethylenimine. Proc Natl Acad Sci USA 92(16):7297-7301.
20. Jimenez JL, Clemente MI, Weber ND, Sanchez J, Ortega P, de la Mata FJ, Gomez R, Garcia D, Lopez-Fernandez LA, Munoz-Fernandez MA 2010. Carbosilane dendrimers to transfect human astrocytes with small interfering RNA targeting human immunodeficiency virus. BioDrugs 24(5):331-343.
21. Kim ID, Lim CM, Kim JB, Nam HY, Nam K, Kim SW, Park JS, Lee JK. 2010. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain. J Control Release 142(3):422-430.
22. Kim JB, Choi JS, Nam K, Lee M, Park JS, Lee JK. 2006. Enhanced transfection of primary cortical cultures using arginine-grafted PAMAM dendrimer, PAMAM-Arg. J Control Release 114(1):110-117.
23. O'Mahony AM, O'Neill MJ, Godinho BMDC, Darcy R, Cryan JF, O'Driscoll CM 2012. Cyclodextrins for non-viral gene and siRNA delivery. Pharm Nanotechnol 1(1):6-14.
24. Chen QM, Butler D, Querbes W, Pandey RK, Ge P, Maier MA, Zhang LG, Rajeev KG, Nechev L, Kotelianski V, Manoharan M, Sah DWY. 2010. Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J Control Release 144(2):227-232.
25. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, Manoharan M, Sah DWY, Zamore PD, Aronin N. 2007. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 104(43):17204-17209.
26. Chang J, Paillard A, Passirani C, Morille M, Benoit JP, Betbeder D, Garcion E. 2012. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res 29(6):1495-1505.
27. Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X, Fu S. 2006. Lectin-conjugated PEG-PLA nanoparticles: Preparation and brain delivery after intranasal administration. Biomaterials 27(18):3482-3490.
28. Cryan JF, Thakker DR, Hoyer D. 2007. Emerging use of non-viral RNA interference in the brain. Biochem Soc Trans 35:411-415.
29. Thakker DR, Hoyer D, Cryan JF. 2006. Interfering with the brain: Use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders. Pharmacol Ther 109(3):413-438.
30. Seyhan AA. 2011. RNAi: A potential new class of therapeutic for human genetic disease. Hum Genet 130(5):583-605.
31. Krol S. 2012. Challenges in drug delivery to the brain: Nature is against us. J Control Release 164(2):145-155.
32. Ohki EC, Tilkins ML, Ciccarone VC, Price PJ. 2001. Improving the transfection efficiency of post-mitotic neurons. J Neurosci Methods 112(2):95-99.
33. Bergen JM, Pun SH. 2008. Analysis of the intracellular barriers encountered by nonviral gene carriers in a model of spatially controlled delivery to neurons. J Gene Med 10(2):187-197.
34. Li SD, Huang L. 2006. Gene therapy progress and prospects: Non-viral gene therapy by systemic delivery. Gene Ther 13(18):1313-1319.
35. Maxwell MM. 2009. RNAi applications in therapy development for neurodegenerative disease. Curr Pharm Des 15(34):3977-3991.
36. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. 2009. Getting into the brain approaches to enhance brain drug delivery. CNS Drugs 23(1):35-58.
37. Posadas I, Javier Guerra F, Cena V. 2010. Nonviral vectors for the delivery of small interfering RNAs to the CNS. Nanomedicine 5(8):1219-1236.
38. Rousselle C, Clair P, Lefauconnier J-M, Kaczorek M, Scherrmann J-M, Temsamani J. 2000. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 57(4):679-686.
39. Cardenas-Aguayo MdC, Kazim SF, Grundke-Iqbal I, Iqbal K. 2013. Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures. PLoS ONE 8(1):e53596.
40. Pardridge W, Kang YS, Buciak J. 1994. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm Res 11(5):738-746.
41. McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare J, Zhu M, Appleyard SM, Wayman GA, Harding JW. 2013. Evaluation of metabolically stabilized angiotensin IV analogs as pro-cognitive/anti-dementia agents. J Pharmacol Exp Ther 344(1):141-154.
42. Senechal Y, Kelly PH, Cryan JF, Natt F, Dev KK. 2007. Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice. J Neurochem 102(6):1928-1940.
43. Thakker DR, Natt F, Husken D, Maier R, Muller M, van der Putten H, Hoyer D, Cryan JF. 2004. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 101(49):17270-17275.
44. Choi BH, Ha Y, Ahn C-H, Huang X, Kim J-M, Park SR, Park H, Park HC, Kim SW, Lee M. 2007. A hypoxia-inducible gene expression system using erythropoietin 3′ untranslated region for the gene therapy of rat spinal cord injury. Neurosci Lett 412(2):118-122.
45. Hughes TS, Langer SJ, Johnson KW, Chavez RA, Watkins LR, Milligan ED, Leinwand LA. 2009. Intrathecal injection of naked plasmid DNA provides long-term expression of secreted proteins. Mol Ther 17(1):88-94.
46. Lewis J, Melrose H, Bumcrot D, Hope A, Zehr C, Lincoln S, Braithwaite A, He Z, Ogholikhan S, Hinkle K, Kent C, Toudjarska I, Charisse K, Braich R, Pandey RK, Heckman M, Maraganore DM, Crook J, Farrer MJ. 2008. In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener 3:19.
47. McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA 2010. Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE 5(8):e12122.
48. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJC, Martin P, Bevan S, Fox A, Ganju P, Wishart W, Hall J. 2004. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 32(5):e49.
49. O'Mahony AM, Desgranges S, Ogier J, Quinlan A, Devocelle M, Darcy R, Cryan J, O'Driscoll C 2012. In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-octaarginine: Towards a formulation strategy for non-viral neuronal siRNA delivery. Pharm Res 30(4):1086-1098.
50. O'Mahony AM, Godinho BMDC, Ogier J, Devocelle M, Darcy R, Cryan JF, O'Driscoll CM 2012. Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery. ACS Chem Neurosci 10(3):744-752.
51. Pulford B, Reim N, Bell A, Veatch J, Forster G, Bender H, Meyerett C, Hafeman S, Michel B, Johnson T, Wyckoff AC, Miele G, Julius C, Kranich J, Schenkel A, Dow S, Zabel MD. 2010. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrPC on neuronal cells and PrPRES in infected cell cultures. Plos One 5(6):e11085.
52. Whitehead KA, Langer R, Anderson DG. 2009. Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 8(2):129-138.
53. Gooding M, Browne LP, Quinteiro FM, Selwood DL. 2012. siRNA delivery: From lipids to cell-penetrating peptides and their mimics. Chem Biol Drug Des 80(6):787-809.
54. Li SD, Chen YC, Hackett MJ, Huang L. 2007. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 16(1):163-169.
55. de Wolf HK, Snel CJ, Verbaan FJ, Schiffelers RM, Hennink WE, Storm G. 2007. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. Int J Pharm 331(2):167-175.
56. Liu F, Shollenberger LM, Conwell CC, Yuan X, Huang L. 2007. Mechanism of naked DNA clearance after intravenous injection. J Gene Med 9(7):613-619.
57. Singh S, Narang AS, Mahato RI. 2011. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res 28(12):2996-3015.
58. Schiffelers RM, de Wolf HK, van Rooy I, Storm G. 2007. Synthetic delivery systems for intravenous administration of nucleic acids. Nanomedicine 2(2):169-181.
59. Gao S, Dagnaes-Hansen F, Nielsen EJB, Wengel J, Besenbacher F, Howard KA, Kjems J. 2009. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 17(7):1225-1233.
60. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher H-P 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014):173-178.
61. Zheng MY, Librizzi D, Kilic A, Liu Y, Renz H, Merkel OM, Kissel T. 2012. Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers. Biomaterials 33(27):6551-6558.
62. Zhang Y, Pardridge WM. 2009. Near complete rescue of experimental parkinson's disease with intravenous, non-viral GDNF gene therapy. Pharm Res 26(5):1059-1063.
63. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. 2004. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 10(11):3667-3677.
64. Allen TM, Sapra P, Moase E. 2002. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett 7(2):217-219.
65. Ishida T, Iden DL, Allen TM. 1999. A combinatorial approach to producing sterically stabilized (stealth) immunoliposomal drugs. FEBS Lett 460(1):129-133.
66. Davis ME. 2009. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 6(3):659-668.
67. O'Mahony AM, Ogier J, Desgranges S, Cryan JF, Darcy R, O'Driscoll CM 2012. A click chemistry route to 2-functionalised PEGylated and cationic β-cyclodextrins: Co-formulation opportunities for siRNA delivery. Org Biomol Chem 10(25):4954-4960.
68. El-Andaloussi S, Lee Y, Lakhal-Littleton S, Li J, Seow Y, Gardiner C, Alvarez-Erviti L, Sargent IL, Wood MJA. 2012. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc 7(12):2112-2126.
69. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. 2011. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29(4):341-345.
70. van den Boorn JG, Schlee M, Coch C, Hartmann G. 2011. siRNA delivery with exosome nanoparticles. Nat Biotech 29(4):325-326.
71. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, Ju S, Mu J, Zhang L, Steinman L, Miller D, Zhang HG. 2011. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 19(10):1769-1779.
72. Li GL, Simon MJ, Cancel LM, Shi ZD, Ji XY, Tarbell JM, Morrison B, Fu BM. 2010. Permeability of endothelial and astrocyte cocultures: In vitro blood-brain barrier models for drug delivery studies. Ann Biomed Eng 38(8):2499-2511.
73. Jiang N, Zhang X, Zheng X, Chen D, Siu K, Wang H, Ichim TE, Quan D, McAlister V, Chen G, Min W-P 2012. A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis. PLoS ONE 7(9):e44138.
74. Guo PX, Coban O, Snead NM, Trebley J, Hoeprich S, Guo SC, Shu Y. 2010. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Delivery Rev 62(6):650-666.
75. Broadstock M, Yanez-Munoz RJ 2012. Challenges for gene therapy of CNS disorders and implications for Parkinson's disease therapies. Hum Gene Ther 23(4):340-343.
76. Perez-Martinez FC, Guerra J, Posadas I, Cena V. 2011. Barriers to non-viral vector-mediated gene delivery in the nervous system. Pharm Res 28(8):1843-1858.
77. O'Brien FE, Dinan TG, Griffin BT, Cryan JF. 2012. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: Clinical significance of in vitro and in vivo findings. Br J Pharmacol 165(2):289-312.
78. Thakker DR, Natt F, Husken D, van der Putten H, Maier R, Hoyer D, Cryan JF. 2005. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry 10(8):782-789.
79. Godinho BMDC, Ogier J, Darcy R, O'Driscoll CM, Cryan JF. 2013. Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: Focus on huntington's disease. Mol Pharm 10(2):640-649.
80. da Cruz MTG, Simoes S, de Lima MCP. 2004. Improving lipoplex-mediated gene transfer into C-6 glioma cells and primary neurons. Exp Neurol 187(1):65-75.
81. da Cruz MTG, Cardoso ALC, de Almeida LP, Simoes S, de Lima MCP. 2005. Tf-lipoplex-mediated NGF gene transfer to the CNS: Neuronal protection and recovery in an excitotoxic model of brain injury. Gene Ther 12(16):1242-1252.
82. Cardoso ALC, Simoes S, de Almeida LP, Pelisek J, Culmsee C, Wagner E, de Lima MCP. 2007. siRNA delivery by a transferrin-associated lipid-based vector: A non-viral strategy to mediate gene silencing. J Gene Med 9(3):170-183.
83. Cardoso ALC, Simoes S, de Almeida LP, Plesnila N, de Lima MCP, Wagner E, Culmsee C. 2008. Tf-lipoplexes for neuronal siRNA delivery: A promising system to mediate gene silencing in the CNS. J Control Release 132(2):113-123.
84. Cardoso ALC, Costa P, de Almeida LP, Simoes S, Plesnila N, Culmsee C, Wagner E, de Lima MCP. 2010. Tf-lipoplex-mediated c-Jun silencing improves neuronal survival following excitotoxic damage in vivo. J Control Release 142(3):392-403.
85. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. 2007. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 21(4):1117-1125.
86. Prades R, Guerrero S, Araya E, Molina C, Salas E, Zurita E, Selva J, Egea G, López-Iglesias C, Teixidó M, Kogan MJ, Giralt E. 2012. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials 33(29):7194-7205.
87. Huang R, Ke W, Han L, Liu Y, Shao K, Jiang C, Pei Y. 2010. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res Bull 81(6):600-604.
88. Huang RQ, Ke WL, Liu Y, Jiang C, Pei YY. 2008. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 29(2):238-246.
89. Pardridge WM. 2008. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem 19(7):1327-1338.
90. Zhang Y, Calon F, Zhu CN, Boado RJ, Pardridge WM. 2003. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 14(1):1-12.
91. Xia CF, Boado RJ, Pardridge WM. 2009. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm 6(3):747-751.
92. Kumar P, Wu HQ, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N. 2007. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39-43.
93. Kim JY, Choi WI, Kim YH, Tae G. 2013. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials 34(4):1170-1178.
94. Gong C, Li XN, Xu LL, Zhang YH. 2012. Target delivery of a gene into the brain using the RVG29-oligoarginine peptide. Biomaterials 33(12):3456-3463.
95. Liu Y, Huang RQ, Han L, Ke WL, Shao K, Ye LY, Lou JN, Jiang C. 2009. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30(25):4195-4202.
96. Hwang DW, Son S, Jang J, Youn H, Lee S, Lee D, Lee YS, Jeong JM, Kim WJ, Lee DS. 2011. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 32(21):4968-4975.
97. Ren JF, Shen S, Wang DG, Xi ZJ, Guo LR, Pang ZQ, Qian Y, Sun XY, Jiang XG. 2012. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33(11):3324-3333.
98. Ke WL, Shao K, Huang RQ, Han L, Liu Y, Li JF, Kuang YY, Ye LY, Lou JN, Jiang C. 2009. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30(36):6976-6985.
99. Heitz F, Morris MC, Divita G. 2009. Twenty years of cell-penetrating peptides: From molecular mechanisms to therapeutics. Br J Pharmacol 157(2):195-206.
100. van Rooy I, Mastrobattista E, Storm G, Hennink WE, Schiffelers RM. 2011. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release 150(1):30-36.
101. Zhang H, Gerson T, Varney ML, Singh RK, Vinogradov SV. 2010. Multifunctional peptide-PEG intercalating conjugates: Programmatic of gene delivery to the blood-brain barrier. Pharm Res 27(12):2528-2543.
102. Georgieva JV, Brinkhuis RP, Stojanov K, Weijers C, Zuilhof H, Rutjes F, Hoekstra D, van Hest JCM, Zuhorn IS. 2012. Peptide-mediated blood-brain barrier transport of polymersomes. Angew Chem Int Ed Engl 51(33):8339-8342.
103. Campbell M, Kiang AS, Kenna PF, Kerskens C, Blau C, O'Dwyer L, Tivnan A, Kelly JA, Brankin B, Farrar GJ, Humphries P. 2008. RNAi-mediated reversible opening of the blood-brain barrier. J Gene Med 10(8):930-947.
104. Kong SD, Lee J, Ramachandran S, Eliceiri BP, Shubayev VI, Lal R, Jin S. 2012. Magnetic targeting of nanoparticles across the intact blood-brain barrier. J Control Release 164(1):49-57.
105. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. 2007. Blood-brain barrier impairment in alzheimer disease-Stability and functional significance. Neurol 68(21):1809-1814.
106. Roberts HC, Roberts TPL, Brasch RC, Dillon WP. 2000. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: Correlation with histologic grade. AJNR Am J Neuroradiol 21(5):891-899.
107. Xia CF, Zhang Y, Zhang Y, Boado RJ, Pardridge WM. 2007. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 24(12):2309-2316.
108. Rohn S, Suttkus A, Arendt T, Ueberham U. 2012. RVG peptide as transfection reagent for specific cdk4 gene silencing in vitro and in vivo. J Drug Targeting 20(4):381-388.
109. Wang W, Singh SK, Li N, Toler MR, King KR, Nema S. 2012. Immunogenicity of protein aggregates-Concerns and realities. Int J Pharm 431(1-2):1-11.
110. Soderquist RG, Mahoney MJ. 2010. Central nervous system delivery of large molecules: Challenges and new frontiers for intrathecally administered therapeutics. Expert Opin Drug Deliv 7(3):285-293.
111. Yao L, Yao S, Daly W, Hendry W, Windebank A, Pandit A. 2012. Non-viral gene therapy for spinal cord regeneration. Drug Discov Today 17(17-18):998-1005.
112. Tumati S, Milnes TL, Yamamura HI, Vanderah TW, Roeske WR, Varga EV. 2008. Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia. Eur J Pharmacol 601(1-3):207-208.
113. Shi L, Tang GP, Gao SJ, Ma YX, Liu BH, Li Y, Zeng JM, Ng YK, Leong KW, Wang S. 2003. Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord. Gene Ther 10(14):1179-1188.
114. Luo MC, Zhang DQ, Ma SW, Huang YY, Shuster SJ, Porreca F, Lai J. 2005. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain 1:29.
115. Tang GP, Zeng JM, Gao SJ, Ma YX, Shi L, Li Y, Too HP, Wang S. 2003. Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: Effects of PEGylation extent. Biomaterials 24(13):2351-2362.
116. Shim MS, Kwon YJ. 2010. Efficient and targeted delivery of siRNA in vivo. FEBS J 277(23):4814-4827.
117. Dalby B, Cates S, Harris A, Ohki EC, Tilkins ML, Price PJ, Ciccarone VC. 2004. Advanced transfection with Lipofectamine 2000 reagent: Primary neurons, siRNA, and high-throughput applications. Methods 33(2):95-103.
118. Krichevsky AM, Kosik KS. 2002. RNAi functions in cultured mammalian neurons. Proc Natl Acad Sci USA 99(18):11926-11929.
119. Yu JY, DeRuiter SL, Turner DL. 2002. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 99(9):6047-6052.
120. Tonges L, Lingor P, Egle R, Dietz GPH, Fahr A, Bahr M. 2006. Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons. RNA 12(7):1431-1438.
121. Abdallah B, Hassan A, Benoist C, Goula D, Behr JP, Demeneix BA. 1996. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: Polyethylenimine. Hum Gene Ther 7(16):1947-1954.
122. Horbinski C, Stachowiak MK, Higgins D, Finnegan SG. 2001. Polyethyleneimine-mediated transfection of cultured postmitotic neurons from rat sympathetic ganglia and adult human retina. BMC Neurosci 2:2.
123. O'Mahony AM, Doyle D, Darcy R, Cryan JF, O'Driscoll CM 2012. Characterisation of cationic amphiphilic cyclodextrins for neuronal delivery of siRNA: Effect of reversing primary and secondary face modifications. Eur J Pharm Sci 47:896-903.
124. Gupta B, Levchenko TS, Torchilin VP. 2005. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57(4):637-651.
125. Ifediba MA, Medarova Z, Ng SW, Yang JZ, Moore A. 2010. siRNA delivery to CNS cells using a membrane translocation peptide. Bioconjug Chem 21(5):803-806.
126. Pham W, Zhao BQ, Lo EH, Medarova Z, Rosen B, Moore A. 2005. Crossing the blood-brain barrier: A potential application of myristoylated polyarginine for in vivo neuroimaging. Neuroimage 28(1):287-292.
127. Davidson TJ, Harel S, Arboleda VA, Prunell GF, Shelanski ML, Greene LA, Troy CM. 2004. Highly efficient small interfering RNA delivery to primary mammalian neurons induces microRNA-like effects before mRNA degradation. J Neurosci 24(45):10040-10046.
128. Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, Aziz F, Sakurai M, Ribe EM, Troy CM, Mercken M, Jung SS, Palmeri A, Arancio O. 2011. Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 69(5):819-830.
129. MacKay JA, Li W, Huang Z, Dy EE, Huynh G, Tihan T, Collins R, Deen DF, Szoka FC. 2008. HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery. Mol Ther 16(5):893-900.
130. Zeng JM, Wang X, Wang S. 2007. Self-assembled ternary complexes of plasmid DNA, low molecular weight polyethylenimine and targeting peptide for nonviral gene delivery into neurons. Biomaterials 28(7):1443-1451.
131. Berhanu DA, Rush RA. 2008. Targeted silencing of TrkA expression in rat forebrain neurons via the p75 receptor. Neuroscience 153(4):1115-1125.
132. Martinez-Fong D, Bannon MJ, Trudeau LE, Gonzalez-Barrios JA, Arango-Rodriguez ML, Hernandez-Chan NG, Reyes-Corona D, Armendariz-Borunda J, Navarro-Quiroga I 2012. NTS-Polyplex: A potential nanocarrier for neurotrophic therapy of Parkinson's disease. Nanomedicine 8(7):1052-1069.
133. Park IK, Lasiene J, Chou SH, Horner PJ, Pun SH. 2007. Neuron-specific delivery of nucleic acids mediated by Tet(1)-modified poly(ethylenimine). J Gene Med 9(8):691-702.
134. Martinez-Fong D, Navarro-Quiroga I, Ochoa I, Alvarez-Maya I, Meraz MA, Luna J, Arias-Montano JA 1999. Neurotensin-SPDP-poly-L-lysine conjugate: A nonviral vector for targeted gene delivery to neural cells. Mol Brain Res 69(2):249-262.
135. Alvarez-Maya I, Navarro-Quiroga I, Meraz-Rios MA, Aceves J, Martinez-Fong D 2001. In vivo gene transfer to dopamine neurons of rat substantia nigra via the high-affinity neurotensin receptor. Mol Med 7(3):186-192.
136. Navarro-Quiroga I, Gonzalez-Barrios JA, Barron-Moreno F, Gonzalez-Bernal V, Martinez-Arguelles DB, Martinez-Fong D 2002. Improved neurotensin-vector-mediated gene transfer by the coupling of hemagglutinin HA2 fusogenic peptide and Vp1 SV40 nuclear localization signal. Mol Brain Res 105(1-2):86-97.
137. Gonzalez-Barrios JA, Lindahl M, Bannon MJ, Anaya-Martinez V, Flores G, Navarro-Quiroga I, Trudeau LE, Aceves J, Martinez-Arguelles DB, Garcia-Villegas R, Jimenez I, Segovia J, Martinez-Fong D 2006. Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol Ther 14(6):857-865.
138. Kwon EJ, Bergen JM, Park IK, Pun SH. 2008. Peptide-modified vectors for nucleic acid delivery to neurons. J Control Release 132(3):230-235.
139. Uno Y, Piao W, Miyata K, Nishina K, Mizusawa H, Yokota T. 2011. High-density lipoprotein facilitates in vivo delivery of alpha-tocopherol-conjugated short-interfering RNA to the brain. Hum Gene Ther 22(6):711-719.
140. Agrawal A, Min D-H, Singh N, Zhu H, Birjiniuk A, von Maltzahn G, Harris TJ, Xing D, Woolfenden SD, Sharp PA, Charest A, Bhatia S. 2009. Functional delivery of siRNA in mice using dendriworms. ACS Nano 3(9):2495-2504.
141. Zou S, Scarfo K, Nantz MH, Hecker JG. 2010. Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells. Int J Pharm 389(1-2):232-243.
142. Kabanov AV. 2006. Polymer genomics: An insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev 58(15):1597-1621.
143. Nunes A, Al-Jamal KT, Kostarelos K. 2012. Therapeutics, imaging and toxicity of nanomaterials in the central nervous system. J Control Release 161(2):290-306.
144. Silva GA. 2006. Neuroscience nanotechnology: Progress, opportunities and challenges. Nat Rev Neurosci 7(1):65-74.
145. Akhtar S. 2010. Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: A focus on toxicogenomics. Expert Opin Drug Metab Toxicol 6(11):1347-1362.
146. Karra N, Borlak J. 2012. Nanostructured biomaterials for overcoming biological barriers. In Nanomedicine and nanotoxicology; Alonso M, Csaba N, Eds. Cambridge, UK: The Royal Society of Chemistry, pp 551-588.
147. Ai J, Biazar E, Jafarpour M, Montazeri M, Majdi A, Aminifard S, Zafari M, Akbari HR, Rad HG. 2011. Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomedicine 6:1117-1127.
148. Lonez C, Vandenbranden M, Ruysschaert JM. 2012. Cationic lipids activate intracellular signaling pathways. Adv Drug Deliv Rev 64(15):1749-1758.
149. Ishida T, Kiwada H. 2008. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 354(1-2):56-62.
150. Ishihara T, Maeda T, Sakamoto H, Takasaki N, Shigyo M, Ishida T, Kiwada H, Mizushima Y, Mizushima T. 2010. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules 11(10):2700-2706.
151. Xu H, Wang KQ, Deng YH, Chen DW. 2010. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials 31(17):4757-4763.
152. Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H. 2011. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Control Release 151(2):149-154.
153. Silva GA. 2009. Nanotechnology applications and approaches for neuroregeneration and drug delivery to the central nervous system. Ann N Y Acad Sci 1199(1):221-230.
154. Jackson AL, Linsley PS. 2010. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9(1):57-67.
155. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS. 2003. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21(6):635-637.
156. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K, Leake D, Marshall WS, Khvorova A. 2006. Off-target effects by siRNA can induce toxic phenotype. RNA 12(7):1188-1196.
157. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, Marshall W, Khvorova A, Linsley PS. 2006. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12(7):1197-1205.
158. Judge A, Maclachlan I. 2008. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 19(2):111-124.
159. Forsbach A, Muller C, Montino C, Kritzler A, Curdt R, Benahmed A, Jurk M, Vollmer J. 2012. Impact of delivery systems on siRNA immune activation and RNA interference. Immunol Lett 141(2):169-180.
160. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BRG. 2003. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5(9):834-839.
161. Walton SP, Wu M, Gredell JA, Chan C. 2010. Designing highly active
162. Manrique C, Compan V, Rosselet C, Duflo SGD. 2009. Specific knock-down of GAD67 in the striatum using naked small interfering RNAs. J Biotechnol 142(3-4):185-192.
163. Shishkina GT, Kalinina TS, Dygalo NN. 2004. Attenuation of alpha(2a)-adrenergic receptor expression in neonatal rat brain by RNA interference or antisense oligonucleotide reduced anxiety in adulthood. Neuroscience 129(3):521-528.
164. Jean A, Conductier G, Manrique C, Bouras C, Berta P, Hen R, Charnay Y, Bockaert J, Compan V. 2007. Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens. Proc Natl Acad Sci USA 104(41):16335-16340.
165. Bonoiu AC, Bergey EJ, Ding H, Hu R, Kumar R, Yong K-T, Prasad PN, Mahajan S, Picchione KE, Bhattacharjee A, Ignatowski TA. 2011. Gold nanorod-siRNA induces efficient in vivo gene silencing in the rat hippocampus. Nanomedicine 6(4):617-630.
166. Vite CH, McGowan JC, Niogi SN, Passini MA, Drobatz KJ, Haskins ME, Wolfe JH. 2005. Effective gene therapy for an inherited CNS disease in a large animal model. Ann Neurol 57(3):355-364.
167. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. 1994. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91(6):2076-2080.
168. Stiles DK, Zhang ZM, Ge P, Nelson B, Grondin R, Ai Y, Hardy P, Nelson PT, Guzaev AP, Butt MT, Charisse K, Kosovrasti V, Tchangov L, Meys M, Maier M, Nechev L, Manoharan M, Kaemmerer WF, Gwost D, Stewart GR, Gash DM, Sah DWY. 2012. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 233(1):463-471.
169. Merkus FWHM, van den Berg MP. 2007. Can nasal drug delivery bypass the blood-brain barrier?: Questioning the direct transport theory. Drugs RD 8(3):133-144.
170. Han I-K, Kim M, Byun H-M, Hwang T, Kim J, Hwang K, Park T, Jung W-W, Chun T, Jeong G-J, Oh Y-K 2007. Enhanced brain targeting efficiency of intranasally administered plasmid DNA: An alternative route for brain gene therapy. J Mol Med 85(1):75-83.
171. Kim I-D, Shin J-H, Kim S-W, Choi S, Ahn J, Han P-L, Park J-S, Lee J-K 2012. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther 20(4):829-839.
172. Adler-Moore J, Proffitt RT. 2002. AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 49(suppl 1):21-30.
173. Fassas A, Anagnostopoulos A. 2005. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 46(6):795-802.
174. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. 2010. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067-1070.
175. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Roeder N, Loeffler K, Lange C, Fechtner M, Moepert K, Fisch G, Dames S, Arnold W, Jochims K, Giese K, Wiedenmann B, Scholz A, Kaufmann J. 2008. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68(23):9788-9798.
176. Schneider, Christian K; Salmikangas, Paula; Jilma, Bernd; Flamion, Bruno; Todorova, Lyubina Racheva; Paphitou, Anna; Haunerova, Ivana; Maimets, Toivo; Trouvin, Jean-Hugues; Flory, Egbert; Tsiftsoglou, Asterios; Sarkadi, Balazs; Gudmundsson, Kolbeinn; O'Donovan, Maura; Migliaccio, Giovanni; Ancans, Janis; Maciulaitis, Romaldas; Robert, Jean-Louis; Samuel, Anthony; Ovelgonne, Johannes H; Hystad, Marit; Fal, Andrzej Mariusz; Lima, Beatriz Silva; Moraru, Anca Stela; Turcani, Peter; Zorec, Robert; Ruiz, Sol; Akerblom, Lennart; Narayanan, Gopalan; Kent, Alastair; Bignami, Fabrizia; Dickson, J George; Niederwieser, Dietger; Figuerola-Santos, Maria-Angeles; Reischl, Ilona G; Beuneu, Claire; Georgiev, Rosen; Vassiliou, Maria; Pychova, Alena; Clausen, Mette; Methuen, Taina; Lucas, Sophie; Schussler-Lenz, Martina; Kokkas, Vasilios; Buzas, Zsuzsanna; MacAleenan, Niall; Galli, Maria Cristina; Line, Aija; Gulbinovic, Jolanta; Berchem, Guy; Fraczek, Mariusz; Menezes-Ferreira, Margarida; Vilceanu, Nela; Hrubisko, Mikulas; Marinko, Petra; Timon, Marcos; Cheng, Wing; Crosbie, George Andrew; Meade, Nick; di Paola, Michelino Lipucci; VandenDriessche, Thierry; Ljungman, Per; D'Apote, Lucia; Oliver-Diaz, Olga; Buttel, Isabel; Celis, Patrick. 2010. Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 9(3):195-201.
177. Van Wilder P. 2012. Advanced Therapy Medicinal Products (ATMP)and exemptions to the Regulation 1394/2007: How confident can we be? An exploratory analysis. Front Pharmacol 3:12.
178. Assi H, Candolfi M, Baker G, Mineharu Y, Lowenstein PR, Castro MG. 2012. Gene therapy for brain tumors: Basic developments and clinical implementation. Neurosci Lett 527(2):71-77.
179. Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, Rose C, Krishna G, Davies JE, Ttofi E, Underwood BR, Rubinsztein DC. 2008. Huntington's disease: From pathology and genetics to potential therapies. Biochem J 412:191-209.
180. Kostarelos K, Miller AD. 2005. Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors. Chem Soc Rev 34(11):970-994.
181. Zhang Y, Boado RJ, Pardridge WM. 2003. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med 5(12):1039-1045.